GSK's RSV Vaccine Scores Approval In UK For Older Adults
Portfolio Pulse from Vandana Singh
The U.K. Medicines and Healthcare Products Regulatory Agency has approved GSK Plc's Arexvy, a vaccine for respiratory syncytial virus (RSV), for adults aged 60 and older. The approval is supported by data from a phase 3 vaccine efficacy trial. In June, the U.S. CDC's Advisory Committee recommended the use of RSV vaccines from Pfizer Inc and GSK for older adults. GSK shares are down 0.03% at $33.80 during the premarket session on the last check Monday.
July 10, 2023 | 1:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
GSK's RSV vaccine has been approved in the UK for adults aged 60 and older. Despite this, GSK's shares are down 0.03% in premarket trading.
The approval of GSK's RSV vaccine in the UK is a positive development for the company. However, the slight decrease in GSK's share price suggests that the market has not yet fully reacted to this news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
The U.S. CDC's Advisory Committee has recommended the use of RSV vaccines from Pfizer and GSK for older adults.
The recommendation of Pfizer's RSV vaccine by the U.S. CDC's Advisory Committee is a positive development for the company. However, the impact on Pfizer's stock price is not clear from the news.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50